CAR T-cell Therapy
Chronic Lymphocytic Leukemia
Head & Neck Cancers
Immunotherapy in GU Cancers
Immunotherapy in Lung Cancer
Immunotherapy in Melanoma
Mantle Cell Lymphoma
Melanoma & Skin Cancer
Oncology Nursing News
Precision Medicine in Oncology
Special Reports in Personalized Cancer Care
SELECT A TOPIC
Expert Discusses Developments in HER2+ Breast Cancer
A. Jo Chien, MD, discusses emerging agents and other developments in HER2-positive breast cancer.
Nivolumab Misses OS Endpoint in SCLC Study
Single-agent nivolumab (Opdivo) did not improve overall survival compared with standard topotecan or amrubicin, where approved, in patients with small cell lung cancer who relapsed following platinum-based chemotherapy.
Lead Investigator Discusses Frontline Pembrolizumab in NSCLC
Gilberto Lopes, MD, discusses the KEYNOTE-042 results and ongoing developments with immunotherapy in NSCLC.
Expert Highlights FLT3 Inhibitors in AML
Mary-Beth Percival, MD, discusses the ongoing development of FLT3 inhibitors and other current research in patients with AML.
Emerging Agents Offer Hope in Late Relapse Myeloma
Sandy Wong, MD, discusses emerging agents being explored for the treatment of patients with multiple myeloma in late relapse.
I-SPY Trials Lead Investigator Discusses Successes and Goals
Laura J. Esserman, MD, MBA, discusses the goals of the I-SPY trials and their impact thus far on patients with high-risk early breast cancer.
FDA Panel Backs Rituximab Biosimilar
The FDA’s Oncologic Drugs Advisory Committee voted 16-0 recommending approval of the rituximab biosimilar CT-P10 for 3 non-Hodgkin lymphoma indications.
Immunotherapy Combos, Immune Agonists Part of Future TNBC Paradigm
Hope S. Rugo, MD, discusses the highly anticipated studies of immunotherapy in triple-negative breast cancer and where the class of agents optimally fits in the landscape.
Individualized Regimens Instrumental After Early Relapse in Myeloma
Michael Green, MD, discusses treatment strategies following early relapse in multiple myeloma.
Combination Trials Signal Next Wave of Treatment for CLL
Within the last decade, the FDA has approved 8 new agents for the treatment of patients with chronic lymphocytic leukemia.
<< Prev Page
Next Page >>
Upfront PD-1 Inhibitor Monotherapy in Advanced NSCLC
Conventional View May Not Apply for All Triple-Negative Breast Cancers
Expanded FDA Clearances Speed Scalp Cooling Acceptance in Oncology Community
Predictive Value Examined Among Genomic Tests for Breast Cancer
Molecular Profiling in Metastatic Breast Cancer: Not Yet Standard of Care, But May Be in Near Future
Covering Every Angle of Oncology Practice. Click a cover below, to view more.
American Journal of Managed Care
Oncology Nursing News
Physicians' Education Resource
Physician's Money Digest
Specialty Pharmacy Times
Terms & Conditions
2 Clarke Drive
Cranbury, NJ 08512
Copyright OncLive 2006-2018
Intellisphere, LLC. All Rights Reserved.